MedTrace Logo

Satiety and Glucose Indices in Adults

NCT02929849 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-05-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether an herb with known alpha-glucosidase inhibitor properties (Salacia Chinensis, SC), affects postprandial appetite ratings and glucose indices in overweight/obese individuals.

Conditions

Interventions

DIETARY_SUPPLEMENT

300 mg SC

Salacia (T1) capsule given with breakfast (mixed meal tolerance test)

DIETARY_SUPPLEMENT

500 mg SC

Salacia (T2) capsule given with breakfast (mixed meal tolerance test)

DIETARY_SUPPLEMENT

Placebo

Placebo capsule given with breakfast (mixed meal tolerance test)

Sponsors & Collaborators

  • OmniActive Health Technologies

    collaborator INDUSTRY

  • Rutgers University

    lead OTHER

Principal Investigators

  • Sue Shapses, PhD · Rutgers University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-06-30
Completion
2017-01-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02929849 on ClinicalTrials.gov